阿托伐他汀治疗对急性冠脉综合征患者血浆CRP和IL-6水平的影响

The change of serum CRP and IL-6 in patients with ACS and the effect of atorvastatin treatment on levels of serum CRP and IL-6

目的探讨阿托伐他汀干预对急性冠脉综合征(ACS)患者血浆C反-应蛋白(CRP)和白介素-6(IL-6)水平的影响。方法采用随机开放法将62例ACS分为阿托伐他汀治疗组和常规对照组进行为期4周的干预,分别测定治疗前及治疗后2周患者血浆CRP和IL-6的浓度变化,比较治疗前后的血浆CRP及IL-6水平变化。结果急性冠脉综合征患者血清CRP及IL-6水平明显升高,治疗4周后,阿托伐他汀治疗组血浆CRP及IL-6水平均明显下降,而常规对照组CRP和IL-6水平无明显变化。结论ACS的发生与机体炎症反应激活有关。阿托伐他汀能够降低血浆CRP和IL-6水平,在ACS的治疗中具有重要作用。

Objective To discuss the effect of atorvastatin treatment on levels of serum C-reactive protein （CRP） and interleukin-6（IL-6） in patients with acute coronary syndrome. Methods 62 patients with acute coronary syndrome were randomly divided into two groups. The treatment group were treated with atorvastatin and the control group were treated with convention medicine. Before and after two weeks treatment the symptoms were observed, the CRP and IL-6 were analyzed. Results After being treated two weeks , the CRP and IL-6 decreased distinctly, the difference had statistical significance （P 〈 0.01 ） ; the levels of CRP and IL-6 were lower in treatment group than those in control group, the difference had statistical significance （P 〈 0.01 ）. Conclusion CRP and IL-6 participated in the pathogenesis of acute coronary syndrome. Atorvastatin Treatment has significant effect on inflammatory reaction and improving prognosis, can treat acute coronary syndrome preferably.